The findings to date indicate that GEP44 is a promising drug that overcomes the adverse side effects associated with existing GLP-1R agonist medications [5, 46] to treat obesity and/or T2DM. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.